title: A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer.
abstract: BACKGROUND
  A Joint Expert Panel recently published guidelines for adjuvant cisplatin-based chemotherapy, recommending routine use in patients with completely resected stage II (T1-2N1 and T3N0) non-small-cell lung cancer (NSCLC). However, these two tumor subgroups should be considered as different entities. While the efficacy of adjuvant chemotherapy has been established in patients with T1-2N1 NSCLC, its benefit in patients with T3N0 tumor remains questionable.
  
  
  METHODS
  We performed an extensive review of the literature using the Joint Expert Panel guidelines as a start point. Altogether, we identified 76 potentially relevant articles. Basing on inclusion and exclusion criteria, 23 of the 76 articles were eventually included in this review.
  
  
  RESULTS
  After careful evaluation of the selected articles, we found no information on the effect of adjuvant chemotherapy in patients with T3N0 NSCLC.
  
  
  CONCLUSIONS
  In the absence of evidence-based data, we recommend that the lack of information on the efficacy of adjuvant chemotherapy for T3N0 tumors be discussed with patients and propose chemotherapy as an individual option. While the efficacy of adjuvant chemotherapy will be difficult to assess prospectively through a large randomized clinical trial, a pooled-analysis of the existing data would quickly and with a limited effort provide a preliminary answer.
authors.affiliation: New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy. tommaso.de-pas@ieo.it
authors.forename: Tommaso
authors.initials: T
authors.lastname: De Pas
authors.forename: Sara
authors.initials: S
authors.lastname: Raimondi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pelosi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Spaggiari
authors.forename: Fillipo
authors.initials: F
authors.lastname: De Braud
authors.forename: Giulia
authors.initials: G
authors.lastname: Veronesi
authors.forename: Patrick
authors.initials: P
authors.lastname: Maisonneuve
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003657:Decision Making; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D009864:Ontario; D010043:Outcome and Process Assessment, Health Care; D010358:Patient Participation; D011013:Pneumonectomy; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014481:United States
chemical_list: D002945:Cisplatin